A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells.

摘要: Current genomic and gene expression analyses provide versatile tools to improve cancer chemotherapy. However, it is still difficult predict whether each patient responds a particular regimen or not. To chemosensitivity in with colorectal cancer, we developed an evaluation method using the primary tumor-initiating cells (TIC, aka stem cells) xenografted nude mice subcutaneously (patient-derived spheroid xenografts; PDSX). Simultaneously, also prepared conventional patient-derived xenografts (PDX) from same patients' tumors compared dosing results those of PDSXs. We further chemosensitivities PDSXs 7 patients who had been given regimens such as FOLFOX FOLFIRI treat their metastatic lesions. As per results, PDSX provided much more precise predictable tumor growth less variance than PDX, although both retained epithelial characteristics tumors. Likewise, drug-dosing tests showed essentially PDXs PDSXs, stronger statistical power Notably, was precisely reflected that along clinical course until resistance emerged at terminal stage. This "paraclinical" xenograft trials may help selection chemotherapy efficacious for patient, and, importantly, avoiding inefficient ones by which can lose precious time QOL. Furthermore, be employed evaluations off-label uses chemotherapeutics compassionate yet-unapproved new drugs personalized therapies. Mol Cancer Ther; 17(10); 2187-96. ©2018 AACR.